<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03273062</url>
  </required_header>
  <id_info>
    <org_study_id>1087860-3</org_study_id>
    <nct_id>NCT03273062</nct_id>
  </id_info>
  <brief_title>A Trial Evaluating Effects of COMT Inhibition in Patients With Acquired Brain Injury</brief_title>
  <official_title>A Double-blind, Placebo-controlled Clinical Trial to Evaluate the Effects of Catechol-O-Methyltransferase (COMT) Inhibition on Cognition and Neuropsychiatric Symptoms in Patients With a History of Acquired Brain Injuries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheppard Pratt Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lieber Institute for Brain Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sheppard Pratt Health System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a follow-up study for an ongoing open label trial conducted by the Sheppard
      Pratt-Lieber Research Institute utilizing the catechol-O-methyl-transferase (COMT) inhibitor
      Tolcapone to evaluate its effects on cognition and neuropsychiatric symptoms in patients with
      brain injuries (BI).

      In this study, investigators will conduct a double-blind, placebo-controlled clinical trial
      utilizing a crossover design to study the effects of two weeks of Tolcapone 200mg
      administered three times a day (total of 600mg/day) on cognitive performance. Physical,
      emotional, cognitive and social functioning will also be evaluated through participant and
      proxy report. The investigators are planning to randomize a total of 12 patients with a
      history of acquired brain injury (BI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study is a follow-up study for an ongoing open label trial conducted by the
      Sheppard Pratt-Lieber Research Institute utilizing the catechol-O-methyl-transferase (COMT)
      inhibitor Tolcapone to evaluate its effects on cognition and neuropsychiatric symptoms in
      patients with brain injuries (BI).

      The outcome measures utilized in this study were chosen based on the available data from the
      currently ongoing open-label clinical trial. The proposed study will utilize the same study
      medication at the same dose and frequency. In addition, the length of administration of study
      medication (two weeks) is identical. In the proposed study, investigators will conduct a
      double-blind, placebo-controlled clinical trial utilizing a crossover design to study the
      effects of two weeks of Tolcapone 200mg administered three times a day (total of 600mg/day)
      on cognitive performance. Physical, emotional, cognitive and social functioning will be
      evaluated through participant and proxy report. The investigators are planning to randomize a
      total of 12 patients with BI.

      The cross-over design requires two 2-week long study periods during which the participant
      receives either Tolcapone two 100mg capsules three times a day (total of 600mg/day) or
      placebo. Participants will be randomly assigned to two sequence groups either starting with
      Tolcapone treatment (T-P group) or placebo (P-T group). Investigators and participants will
      be blind to the study group assignment and hence blind to the treatment (Tolcapone vs.
      placebo) that subjects receive at a given time. The study periods are separated by a &quot;washout
      period&quot; that is at least two weeks and maximally 4 weeks long to reduce the potential for
      carryover effects. Patient reported outcomes will be obtained a total of four times, twice
      prior to the start of each respective study period (Pre-Study Period Visits I &amp; II) as well
      as at the end of each study period (Outcome Measures Visits I &amp; II). Cognitive outcome
      measures will be obtained twice throughout the study, at the end of each respective study
      period (Outcome Measures Visits I &amp; II).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 20, 2017</start_date>
  <completion_date type="Anticipated">July 20, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 20, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Interventional clinical trial with a double-blind, randomized placebo-controlled crossover design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The participant, respective care provider, as well as the investigator and research coordinator (&quot;outcomes assessor&quot;) will all be blind to the order of placebo or medication (Tolcapone) administration in this two-arm, crossover study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>NIH Toolbox Fluid Cognitive Battery</measure>
    <time_frame>Administered on the 14th day of Tolcapone or Placebo treatment (i.e. during each Outcome Measures Visit).</time_frame>
    <description>This battery is a measure of cognitive performance derived from a battery of five cognitive assessments.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TBI Quality-of-Life Measurement System</measure>
    <time_frame>Administered prior to the start of Tolcapone oe Placebo treatment (i.e. during each Pre-Study Visit) and on the 14th day of Tolcapone or Placebo treatment (i.e. during each Outcome Measures Visit).</time_frame>
    <description>A patient reported outcome measure assessing physical, emotional, cognitive and social functioning. Quality of Life Measure is a computer adaptive questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frontal Systems Behavior Scale</measure>
    <time_frame>Administered prior to the start of Tolcapone oe Placebo treatment (i.e. during each Pre-Study Visit) and on the 14th day of Tolcapone or Placebo treatment (i.e. during each Outcome Measures Visit).</time_frame>
    <description>A patient reported outcome measure, and proxy reported outcome measure, assessing neuropsychiatric symptoms associated with prefrontal cortical dysfunction</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Brain Injuries</condition>
  <condition>Brain Injuries, Traumatic</condition>
  <condition>Brain Injury, Chronic</condition>
  <arm_group>
    <arm_group_label>Study Period 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>15 days of Tolcapone 200mg TID
OR
Placebo Comparator 15 days of Placebo pill TID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Period 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>15 days of Placebo pill TID
OR
Active Comparator 15 days of Tolcapone 200mg TID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolcapone 200 MG</intervention_name>
    <description>Tolcapone 200 MG TID</description>
    <arm_group_label>Study Period 1</arm_group_label>
    <arm_group_label>Study Period 2</arm_group_label>
    <other_name>Tasmar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, TID Placebo will be in capsules that are identical in appearance to intervention drug, Tolcapone.</description>
    <arm_group_label>Study Period 1</arm_group_label>
    <arm_group_label>Study Period 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Capacity for written informed consent

          -  Ages 18-70 years, inclusive

          -  Diagnosis of a BI including mild, moderate, or severe TBI, or other acquired BI and
             post-BI development of neuropsychiatric complaints.

          -  Index event resulting in Traumatic or Acquired Brain Injury occurred &gt;12 months prior
             to trial initiation

          -  A current or former patient at the clinics of the Sheppard Pratt Neuropsychiatry
             Program or another Sheppard Pratt outpatient clinic with medical documentation of BI

          -  Proficient in the English language

          -  Available to come to Sheppard Pratt Towson for the baseline evaluation and testing and
             for the duration of the protocol

          -  Stable neurological and psychiatric symptomatology for two months prior to trial
             initiation as determined by the referring Sheppard Pratt physician.

          -  Stable medication dose and regimen for two months prior to trial initiation (based on
             a review of medical chart)

        Exclusion Criteria:

          -  History of, or active, liver disease or abnormal liver function tests-if the patient
             currently has elevated Alanine Transaminase (ALT) or Aspartate Transaminase (AST)
             levels that exceed 2 times the upper limit of normal [Normal Reference Ranges ALT
             (Male: 4-40 IU/L, Female: 4-40 IU/L), AST (Male: 4-31 IU/L, Female: 4-37 IU/L) or the
             ratio of AST: ALT has exceeded 2:1

          -  Uncontrolled hypo-or hypertension based on Joint National Committee criteria (JNC7)
             Hypotension: Systolic &lt;90mmHg or diastolic &lt;60mmHg Hypertension: Systolic &gt;140mmHg or
             diastolic &gt;90 mmHg)

          -  Active alcohol use disorder, as defined by DSM-5, of any severity mild, moderate, or
             severe

          -  Active illicit substance use, resulting in a substance use disorder as defined by
             DSM-5, of any severity mild, moderate, or severe

          -  Patient is currently taking Tolcapone or any of the following medications that can
             interact with Tolcapone resulting in an adverse event: another COMT inhibitor,
             benserazide, Î±-methyldopa, Dobutamine, Apomorphine, Isoproterenol, Clozapine, MAO
             inhibitor

          -  Known allergy or serious adverse reaction to Tolcapone

          -  Participated in any investigational drug trial within the past 30 days.

          -  Pregnant or planning to become pregnant during the study period

          -  Breastfeeding or planning to breastfeed during the study period.

          -  Presence of severe pre-morbid/pre-BI cognitive impairment or behavioral dysfunction,
             as per informant or medical documentation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert J Schloesser, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheppard Pratt Health System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert J Schloesser, MD</last_name>
    <phone>410-938-4610</phone>
    <email>rschloesser@sheppardpratt.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emily A Berich, BS</last_name>
    <phone>410-938-4610</phone>
    <email>eberich@sheppardpratt.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sheppard Pratt Health System</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert J Schloesser, MD</last_name>
      <phone>410-938-4666</phone>
      <email>rscloesser@sheppardpratt.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2017</study_first_submitted>
  <study_first_submitted_qc>September 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2017</study_first_posted>
  <last_update_submitted>September 1, 2017</last_update_submitted>
  <last_update_submitted_qc>September 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheppard Pratt Health System</investigator_affiliation>
    <investigator_full_name>Robert Schloesser, MD</investigator_full_name>
    <investigator_title>Executive Director, Sheppard Pratt-Lieber Research Institute, Inc.</investigator_title>
  </responsible_party>
  <keyword>Brain Injury</keyword>
  <keyword>Traumatic Brain Injury</keyword>
  <keyword>Acquired Brain Injury</keyword>
  <keyword>Cognition</keyword>
  <keyword>Neuropsychiatric Symptopms</keyword>
  <keyword>COMT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Brain Injury, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolcapone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

